RU2014127714A - ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile - Google Patents
ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile Download PDFInfo
- Publication number
- RU2014127714A RU2014127714A RU2014127714A RU2014127714A RU2014127714A RU 2014127714 A RU2014127714 A RU 2014127714A RU 2014127714 A RU2014127714 A RU 2014127714A RU 2014127714 A RU2014127714 A RU 2014127714A RU 2014127714 A RU2014127714 A RU 2014127714A
- Authority
- RU
- Russia
- Prior art keywords
- antigen
- seq
- toxa
- toxb
- immunogenic composition
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims abstract 7
- 229960005486 vaccine Drugs 0.000 title claims 8
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- 239000000427 antigen Substances 0.000 claims abstract 98
- 102000036639 antigens Human genes 0.000 claims abstract 98
- 108091007433 antigens Proteins 0.000 claims abstract 98
- 239000000203 mixture Substances 0.000 claims abstract 30
- 230000002163 immunogen Effects 0.000 claims abstract 21
- 229920001184 polypeptide Polymers 0.000 claims abstract 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 7
- 150000001413 amino acids Chemical class 0.000 claims abstract 7
- 239000012634 fragment Substances 0.000 claims abstract 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 6
- 241000124008 Mammalia Species 0.000 claims 4
- 239000013256 coordination polymer Substances 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 1
- 101710182223 Toxin B Proteins 0.000 claims 1
- 101710182532 Toxin a Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1121149.7 | 2011-12-08 | ||
| GB201121149A GB201121149D0 (en) | 2011-12-08 | 2011-12-08 | Clostridium difficile toxin-based vaccine |
| GB1217321.7 | 2012-09-27 | ||
| GBGB1217321.7A GB201217321D0 (en) | 2012-09-27 | 2012-09-27 | Vaccine |
| PCT/IB2012/002955 WO2013084071A2 (en) | 2011-12-08 | 2012-12-07 | Clostridium difficile toxin-based vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2014127714A true RU2014127714A (ru) | 2016-01-27 |
Family
ID=47747684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014127714A RU2014127714A (ru) | 2011-12-08 | 2012-12-07 | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile |
Country Status (15)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2781057C2 (ru) * | 2017-03-15 | 2022-10-04 | Новавакс, Инк. | Способы и композиции для индукции иммунного ответа против clostridium difficile |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX347521B (es) | 2011-04-22 | 2017-04-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
| CA2882620A1 (en) * | 2012-09-19 | 2014-03-27 | Novartis Ag | Clostridium difficile polypeptides as vaccine |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| WO2014197651A1 (en) * | 2013-06-05 | 2014-12-11 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
| CA2935375C (en) | 2014-01-06 | 2023-08-08 | The Trustees Of The University Of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| PT3160500T (pt) * | 2014-06-25 | 2019-11-11 | Glaxosmithkline Biologicals Sa | Composição imunogénica de clostridium difficile |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US10668140B2 (en) | 2017-02-24 | 2020-06-02 | University Of South Floirida | Non-toxigenic Clostridium difficile spores for use in oral vaccination |
| US10555992B2 (en) | 2017-05-31 | 2020-02-11 | University Of South Florida | Immunogenic proteins against clostridium difficile |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| EP3972638A4 (en) * | 2019-05-21 | 2023-09-13 | The Regents Of The University Of California | VACCINE COMPOSITION FOR CLOSTRIDIUM DIFFICILE |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5916588A (en) | 1984-04-12 | 1999-06-29 | The Liposome Company, Inc. | Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use |
| US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| AU631377B2 (en) | 1988-08-25 | 1992-11-26 | Liposome Company, Inc., The | Affinity associated vaccine |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| ES2055785T3 (es) | 1989-01-17 | 1994-09-01 | Eniricerche Spa | Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas. |
| JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
| KR920703114A (ko) | 1989-07-14 | 1992-12-17 | 원본미기재 | 접합체 백신을 위한 시토킨 및 호르몬 운반체 |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
| EP0471177B1 (en) | 1990-08-13 | 1995-10-04 | American Cyanamid Company | Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| US5750110A (en) | 1992-06-25 | 1998-05-12 | Smithkline Beecham Biologicals, S.A | Vaccine composition containing adjuvants |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| US6239116B1 (en) | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US6429199B1 (en) | 1994-07-15 | 2002-08-06 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules for activating dendritic cells |
| JP2002514886A (ja) | 1994-10-24 | 2002-05-21 | プロメガ コーポレーション | クロストリジウム・ディフィシル疾患の治療及び予防のためのワクチン及び抗トキシン |
| GB9513261D0 (en) | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| DE69610106D1 (de) | 1995-07-07 | 2000-10-05 | Oravax Inc | Toxine und toxoide von clostridium difficile als schleimhautadjuvans |
| US5707829A (en) | 1995-08-11 | 1998-01-13 | Genetics Institute, Inc. | DNA sequences and secreted proteins encoded thereby |
| WO1998008540A1 (en) | 1996-08-28 | 1998-03-05 | Ophidian Pharmaceuticals, Inc. | Multivalent vaccine for clostridium botulinum neurotoxin |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| GB9712347D0 (en) | 1997-06-14 | 1997-08-13 | Smithkline Beecham Biolog | Vaccine |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| AU746859B2 (en) | 1997-06-20 | 2002-05-02 | Imperial College Of Science, Technology And Medicine | Immonogenic fragments of toxin a of clostridium difficile |
| ES2201551T3 (es) | 1997-09-05 | 2004-03-16 | Glaxosmithkline Biologicals S.A. | Emulsiones de aceite en agua que contienen saponinas. |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| JP2002502882A (ja) | 1998-02-12 | 2002-01-29 | アメリカン・サイアナミド・カンパニー | インターロイキン−１２とともに処方された肺炎球菌および髄膜炎菌のワクチン |
| US6303114B1 (en) | 1998-03-05 | 2001-10-16 | The Medical College Of Ohio | IL-12 enhancement of immune responses to T-independent antigens |
| JP2002511423A (ja) | 1998-04-09 | 2002-04-16 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ワクチン |
| US20020009429A1 (en) * | 1999-01-29 | 2002-01-24 | Galagen, Inc. | Pharmaceutical composition comprising a selected antigen and candida species antigen and methods |
| DK1163000T3 (da) | 1999-03-19 | 2008-04-28 | Glaxosmithkline Biolog Sa | Vacciner imod antigener fra bakterier |
| EP1165796A2 (en) | 1999-04-09 | 2002-01-02 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| US6733760B1 (en) * | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
| EP1169456B1 (en) | 1999-04-09 | 2012-07-11 | Intercell USA, Inc. | Recombinant production of Clostridium difficile Toxin A or Toxin B |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| AU2001258107A1 (en) * | 2000-05-10 | 2001-11-20 | Glycodesign Inc. | Designing modulators for glycosyltransferases |
| ATE439372T1 (de) | 2000-10-27 | 2009-08-15 | Novartis Vaccines & Diagnostic | Nukleinsäuren und proteine von gruppen a und b- streptokokken |
| US20040107461A1 (en) * | 2001-03-30 | 2004-06-03 | Padma Commuri | Glucan chain length domains |
| EP1450856B1 (en) | 2001-09-14 | 2009-11-11 | Cytos Biotechnology AG | Packaging of immunostimulatory cpg into virus-like particles: method of preparation and use |
| WO2003024480A2 (en) | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| WO2004041857A2 (en) | 2002-06-17 | 2004-05-21 | Ballard Jimmy D | Mutant of clostridium difficile toxin b and methods of use |
| US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
| SI2857418T1 (en) | 2004-02-06 | 2018-01-31 | University Of Massachusetts | Antibodies against Clostridium difficile toxins and uses thereof |
| AU2005321974B2 (en) | 2004-12-27 | 2011-11-17 | Progenics Pharmaceuticals (Nevada), Inc. | Orally deliverable and anti-toxin antibodies and methods for making and using them |
| US20060228369A1 (en) | 2005-04-11 | 2006-10-12 | Program For Appropriate Technology In Health | Stabilization and preservation of temperature-sensitive vaccines |
| US8852600B2 (en) | 2006-06-08 | 2014-10-07 | The Rockefeller University | Codon-optimized DNA molecules encoding the receptor binding domains of Clostridium difficile toxins A and B, and methods of use thereof |
| CA2659684A1 (en) | 2006-08-02 | 2008-02-07 | Johannes Gutenberg-Universitaet Mainz | Medicament for lct poisoning |
| WO2008152429A1 (en) * | 2007-06-14 | 2008-12-18 | Health Protection Agency | Chemically modified peptides with improved immunogenicity |
| US8524444B2 (en) * | 2007-06-15 | 2013-09-03 | President And Fellows Of Harvard College | Methods and compositions for detections and modulating O-glycosylation |
| US20120020996A1 (en) * | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
| CN102365097A (zh) | 2009-02-20 | 2012-02-29 | 卫生防护机构 | 艰难梭菌毒素的抗体 |
| EP2470664A4 (en) * | 2009-08-27 | 2013-01-16 | Synaptic Res Llc | NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS |
| US10046040B2 (en) | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
| US20120282274A1 (en) | 2009-11-20 | 2012-11-08 | Northshore University Health System Research Institute | Targeting of the c-terminal segment of c.difficile toxin b for improved clinical diagnosis, prevention, and treatment |
| WO2011068953A2 (en) * | 2009-12-02 | 2011-06-09 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
| GB0921288D0 (en) | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
| JP5839411B2 (ja) | 2010-03-30 | 2016-01-06 | フェニックス インク． | 組み換え型毒素タンパク質の高レベルの発現 |
| US8986697B2 (en) * | 2010-04-15 | 2015-03-24 | Progenics Pharmaceuticals, Inc. | Antibodies for the treatment of Clostridium difficile-associated infection and disease |
| SMT201700124T1 (it) | 2010-09-03 | 2017-05-08 | Valneva Austria Gmbh | Polipeptide isolato delle proteine di tossina a e tossina b di c. difficile e relativi usi |
| US8431361B2 (en) | 2010-09-17 | 2013-04-30 | Board Of Regents Of The University Of Oklahoma | Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
| WO2012118693A1 (en) | 2011-02-28 | 2012-09-07 | Northshore University Healthsystem | Methods of diagnosing clostridium difficile infection |
| MX347521B (es) * | 2011-04-22 | 2017-04-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos. |
| ES2743442T3 (es) * | 2011-05-27 | 2020-02-19 | Glaxosmithkline Biologicals Sa | Composición inmunogénica |
| AR087716A1 (es) * | 2011-08-31 | 2014-04-09 | Valent Biosciences Corp | Composiciones reguladoras del crecimiento de plantas, metodos de preparacion y usos de las mismas |
| AR089797A1 (es) * | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
| GB201223342D0 (en) * | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
-
2012
- 2012-12-07 US US14/363,387 patent/US9694063B2/en active Active
- 2012-12-07 SG SG11201402375VA patent/SG11201402375VA/en unknown
- 2012-12-07 IN IN4071CHN2014 patent/IN2014CN04071A/en unknown
- 2012-12-07 AU AU2012349753A patent/AU2012349753A1/en not_active Abandoned
- 2012-12-07 CN CN201280060487.1A patent/CN103974718A/zh active Pending
- 2012-12-07 WO PCT/IB2012/002955 patent/WO2013084071A2/en active Application Filing
- 2012-12-07 RU RU2014127714A patent/RU2014127714A/ru not_active Application Discontinuation
- 2012-12-07 ES ES12826538T patent/ES2704069T3/es active Active
- 2012-12-07 MX MX2014006630A patent/MX2014006630A/es unknown
- 2012-12-07 KR KR1020147018480A patent/KR20140101835A/ko not_active Withdrawn
- 2012-12-07 EP EP12826538.6A patent/EP2788022B1/en active Active
- 2012-12-07 BR BR112014013876A patent/BR112014013876A2/pt not_active IP Right Cessation
- 2012-12-07 JP JP2014545387A patent/JP6084631B2/ja active Active
- 2012-12-07 CA CA2858519A patent/CA2858519A1/en not_active Abandoned
-
2014
- 2014-06-05 IL IL232957A patent/IL232957A0/en unknown
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2781057C2 (ru) * | 2017-03-15 | 2022-10-04 | Новавакс, Инк. | Способы и композиции для индукции иммунного ответа против clostridium difficile |
| RU2781057C9 (ru) * | 2017-03-15 | 2022-11-10 | Новавакс, Инк. | Способы и композиции для индукции иммунного ответа против clostridium difficile |
Also Published As
| Publication number | Publication date |
|---|---|
| US20150132333A1 (en) | 2015-05-14 |
| WO2013084071A2 (en) | 2013-06-13 |
| CN103974718A (zh) | 2014-08-06 |
| MX2014006630A (es) | 2014-07-09 |
| IN2014CN04071A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-10-23 |
| WO2013084071A3 (en) | 2013-11-07 |
| KR20140101835A (ko) | 2014-08-20 |
| JP2015500827A (ja) | 2015-01-08 |
| BR112014013876A2 (pt) | 2019-09-24 |
| US9694063B2 (en) | 2017-07-04 |
| SG11201402375VA (en) | 2014-10-30 |
| CA2858519A1 (en) | 2013-06-13 |
| ES2704069T3 (es) | 2019-03-14 |
| IL232957A0 (en) | 2014-07-31 |
| JP6084631B2 (ja) | 2017-02-22 |
| EP2788022B1 (en) | 2018-10-31 |
| AU2012349753A1 (en) | 2014-06-19 |
| EP2788022A2 (en) | 2014-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014127714A (ru) | ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile | |
| RU2508126C2 (ru) | Композиции для иммунизации против staphylococcus aureus | |
| RU2016111934A (ru) | Иммуногенные композиции коронавируса ближневосточного респираторного синдрома (mers-cov) и способы | |
| JP2011250797A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| Sánchez et al. | Combination of CpG-oligodeoxynucleotides with recombinant ROP2 or GRA4 proteins induces protective immunity against Toxoplasma gondii infection | |
| NO20071609L (no) | Immunogen sammensetning for anvendelse ved vaksinering mot stafylokokker | |
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| JP2012523246A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| UA110806C2 (uk) | Мікобактеріальна антигенна композиція | |
| JP2015500827A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| EA201391200A1 (ru) | Способы и композиции для вакцинации от staphylococcus aureus | |
| MA32819B1 (fr) | Vaccin combine notamment contre la coqueluche acellulaire | |
| EP4226938A3 (en) | Coronavirus vaccine | |
| SI2714910T1 (en) | An immunogenic composition | |
| AU2017272265B2 (en) | Enhancing immunity to tuberculosis | |
| EA201171032A1 (ru) | Схемы лечения с помощью вакцины против гриппа, связанного с пандемическими штаммами | |
| WO2023147092A3 (en) | Coronavirus vaccine | |
| JP2015529677A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| UA110024C2 (uk) | Вакцинний вектор і спосіб посилення імунної відповіді | |
| JP2016504993A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| RU2015107435A (ru) | Композиции и способы для лечения активной инфекции mycobacterium tuberculosis | |
| RU2015100889A (ru) | Вакцины для менингококка серогруппы х | |
| Garg et al. | Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD50 rabies challenge virus standard strain | |
| EA201690057A1 (ru) | Остеопонтин молока млекопитающих для повышения иммунологической реактивности | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170515 |